Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Central diabetes insipidus (CDI) is a hypothalamus-pituitary disease characterized by polyuria and polydipsia due to a vasopressin (AVP) deficiency. It can be inherited or acquired (hereditary CDI and acquired CDI).
Biomarker and diagnostic research for central diabetes insipidus has been reported in the published literature.
Estimated prevalence: 1-9 in 100,000 (Uncommon).
6 clinical trials registered, 5 recruiting. Interventions under study include drug therapy, other interventions, and procedural interventions. Pipeline includes 3 PHASE2, 3 NA. Research is primarily sponsored by academic and government institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT06036004](https://clinicaltrials.gov/study/NCT06036004) |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 12:50 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Oxytocin Substitution Therapy in Patients With Central Diabetes Insipidus |
PHASE2 |
University Hospital, Basel, Switzerland |
RECRUITING |
[NCT06808516](https://clinicaltrials.gov/study/NCT06808516) | Effects of Intranasal Oxytocin on Sexual Well-Being in Patients With Arginine Vasopressin Deficiency and Healthy Controls | PHASE2 | University Hospital, Basel, Switzerland | RECRUITING |
[NCT07361263](https://clinicaltrials.gov/study/NCT07361263) | Plasma Oxytocin Response to Oral Estrogens in Healthy Controls and AVP-Deficiency | NA | University Hospital, Basel, Switzerland | RECRUITING |
[NCT06604975](https://clinicaltrials.gov/study/NCT06604975) | Arginin-stimulated Copeptin in Polyuria-polydipsia Syndrome in Children | NA | Assistance Publique Hopitaux De Marseille | NOT_YET_RECRUITING |
[NCT06676774](https://clinicaltrials.gov/study/NCT06676774) | Effect of Intranasal Oxytocin on Emotion Recognition and Acute Psycho-Social Stress-induced Cortisol Increase in Patients With Central Diabetes Insipidus and Healthy Controls | PHASE2 | University Hospital, Basel, Switzerland | RECRUITING |
211 publications have been identified in PubMed for central diabetes insipidus. Research spans Case Report / Case Series (54%), Review / Meta-Analysis (14%), and Diagnostic / Biomarker (10%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 113 | 54% |
Research summaries | 29 | 14% |
Testing and diagnosis research | 22 | 10% |
Disease patterns and progression | 16 | 8% |
Laboratory research | 14 | 7% |
Clinical study results | 11 | 5% |
Other research | 3 | 1% |
New treatment approaches | 3 | 1% |
Fukuta T (2026). [PMID: 41509149](https://pubmed.ncbi.nlm.nih.gov/41509149/). *Clin Pediatr Endocrinol*. [Case Report / Case Series]
Mohammed BA (2026). [PMID: 41913866](https://pubmed.ncbi.nlm.nih.gov/41913866/). *Cureus*. [Case Report / Case Series]
Zhong K (2026). [PMID: 42164704](https://pubmed.ncbi.nlm.nih.gov/42164704/). *Gland Surg*. [Diagnostic / Biomarker]
Votinov M (2026). [PMID: 41791640](https://pubmed.ncbi.nlm.nih.gov/41791640/). *Progress in neuro-psychopharmacology & biological psychiatry*. [Basic Science / Preclinical]
Alqurashi YG (2026). [PMID: 41964632](https://pubmed.ncbi.nlm.nih.gov/41964632/). *JACC Case Rep*. [Case Report / Case Series]
Hacker P (2026). [PMID: 42164211](https://pubmed.ncbi.nlm.nih.gov/42164211/). *Cureus*. [Case Report / Case Series]
Marques P (2026). [PMID: 42158161](https://pubmed.ncbi.nlm.nih.gov/42158161/). *JCEM Case Rep*. [Case Report / Case Series]
Varaldo E (2026). [PMID: 41499390](https://pubmed.ncbi.nlm.nih.gov/41499390/). *J Clin Endocrinol Metab*. [Basic Science / Preclinical]
Astigarraga I (2026). [PMID: 42101911](https://pubmed.ncbi.nlm.nih.gov/42101911/). *Blood Adv*. [Gene Therapy / Novel Therapeutics]
Kaino A (2026). [PMID: 41553688](https://pubmed.ncbi.nlm.nih.gov/41553688/). *Int J Hematol*. [Diagnostic / Biomarker]